Record title
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
Record identifier
TN_cdi_proquest_miscellaneous_2007980562
Record permalink
https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2007980562
Share
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
About this item
Full title
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
Author / Creator
Publisher
England: Elsevier Ltd
Journal title
The lancet oncology, 2018, Vol.19 (4), p.486-496
Record Identifier
TN_cdi_proquest_miscellaneous_2007980562
Language
English
Formats
Publication information
Publisher
Subjects
More information
Scope and Contents
Contents
Alternative Titles
Full title
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2007980562
Permalink
https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2007980562
Other Identifiers
ISSN
E-ISSN
DOI
